This TOGA Podcast focuses on Small Cell Lung cancer (SCLC) – a type of lung cancer with the poorest prognosis of any lung cancer. Our guests today include Dr Steven Kao, a Medical Oncologist, Associate Professor Stephen Liu, and Dr Rebecca Tay, a Medical Oncologist.
Welcome to the Thoracic Oncology Group of Australasia Podcast series. This TOGA Podcast focuses on Small Cell Lung cancer (SCLC) – a type of lung cancer with the poorest prognosis of any lung cancer. SCLC patients make up about 13% of new lung cancer diagnoses that are characterized by early & rapid spread with only modest progress in its treatment over the last decades. Immunotherapy continues to radically change the way we treat many types of lung cancer and today we explore what these treatments mean for the SCLC patient and the practical implications of using immunotherapies in the clinic. We also discuss future combinations and novel agents in clinical trial development.
Our guests today include Dr Steven Kao, Medical Oncologist from the Chris O’Brien Lifehouse in Sydney Australia, Associate Professor Stephen Liu, Director of Thoracic Oncology & Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Centre of Georgetown University and also Dr Rebecca Tay, a Medical Oncologist from the Royal Hobart Hospital in Tasmania, having recently completed a Clinical Research Fellowship at the Christie NHS Foundation Trust in Manchester.
Thank you for joining us and also thank you to Roche for sponsoring this Podcast.
Useful link: https://www.frontiersin.org/articles/10.3389/fonc.2020.01074/full
Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.